Aktiechat - investeringstips

	10/8 16:08 af Jedi	Can we expect to see Dara phase II data in NHL (the Carina study) within this year. If not, when do you expect data from this study?
	10/8 16:07 af Jan Van de Winkel	In the coming months we expect updates on several of the ongoing MM trials, but it is too early to predict what exactly will be presented at ASH..
	10/8 16:06 af Sukkeralf	Will we get updates from the backbone clinical trial with daratumumab at ASH ? What should the extended trials with Dara-Pom-dex (100 pts), Dara-CFZ-dex (20 patients) and Dara-KRD lead to ?
	10/8 16:05 af Jan Van de Winkel	We currently work with models for the US plus the five largest countries in the EU estimating the fourth line market to be roughly 20,000 patients, the second and third line market is estimated to be around 45,000 patients (these are the populations targetted in POLLUX and CASTOR)..
	10/8 16:04 af jkj	How much bigger patient population are you expeting for Polux and castor in second line, in compare whit current treatment whit dara in mono.
	10/8 16:03 af Jan Van de Winkel	We are focused exclusively on creating truly differentiated medicines for which we very much believe that society will want to support in order to provide new treatment options for patients..
	10/8 16:02 af Bulder	Other companies have been hit hard lately because of expectations of lower drug prices in the US. What are your expectations concerning prices for drugs against MM in the future?
	10/8 16:01 af Jan Van de Winkel	We are actively increasing our investment in both the preclinical and clinical pipelines, which are stronger than ever before in the company's history..
	10/8 16:01 af Mcjean	Can you please tell me what the strategies is for your cash-balance? I know you will use it for later but shouldnt you increase the cash-balance by investment in the meantime?
	10/8 16:00 af Jan Van de Winkel	On top of that we got a second Breakthrough therapy designation from the FDA for daratumumab in July..
	10/8 16:00 af Jan Van de Winkel	Highlights for the quarter were the rapid approval in EU for DARZALEX, and the great data from the POLLUX phase 3 secondline study in MM (dara in combination with revlimid)..
	10/8 15:59 af Jan Van de Winkel	Revenue was up 86%, Expenses up 49% and operating income 158 M DKK vs 212 M DKK, excluding one off the 176 M DKK from the GSK reversal, earnings would have been up 122 M DKK, Cash 3.8 Bn DKK......
	10/8 15:57 af Helge Larsen/PI-redaktør	Although the foreign sell out today, we note that Genmab has had a great Q2. Can you start with giving us an update on key figures and the most important developments in the Q2 ?
	10/8 15:57 af Helge Larsen/PI-redaktør	Great.
	10/8 15:57 af Jan Van de Winkel	Looking forward to some good questions..
	10/8 15:57 af Helge Larsen/PI-redaktør	Jan van de Winkel and David Eatwell. Welcome to the Q & A here on the ProInvestor. We are very happy that you are back in here and ready to answer questions from our investors.
	10/8 15:56 af Jan Van de Winkel	Good afternoon, Jan van de Winkel here, together with David Eatwell, Genmab's CFO.
	10/8 15:51 af Helge Larsen/PI-redaktør	In 10 minutes we begin the online Q&A with Genmab.
	10/8 15:41 af Helge Larsen/PI-redaktør	This session starts in 20 minutes.